Cantex's pipeline has two product candidates in clinical development for diseases where innovative and more effective treatments are greatly needed. DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML). Dicopp® for the treatment of metastatic pancreatic cancer, recurrent/refractory multiple myeloma, and recurrent pediatric sarcoma.
Cantex has two product candidates in clinical development:
DSTAT (formerly known as CX-01):
Licensed to Chimerix, Inc. in July 2019. Continued participation in development via Joint Development Committee.
A new chemical entity, derived from heparin, with very low anticoagulant activity
Neutralizes activity of heparin-binding proteins that play a role in the resistance of leukemia cells to chemotherapy
Randomized Phase 2 study in acute myeloid leukemia (AML) suggested DSTAT + 7+3 improves event-free and relapse-free survival as well as overall survival without additive toxicity
Most patients who achieved complete response remain relapse free 15+ months after initial treatment
Phase 3 clinical trial in AML expected to begin in late 2020.
DSTAT has received Orphan Drug and Fast Track Designations from the FDA for the treatment of AML
Pre-clinical data suggests that DSTAT may reduce inflammation, decrease immune cell infiltration and prevent and treat coagulation disorders associated with acute lung injury
Phase 2/3 study of DSTAT in COVID-19 associated acute lung injury is in progress
Proprietary combination of disulfiram + copper which has been extensively reported to have cancer cell killing mechanisms, including proteasome inhibition and inhibition of activity of DNA repair enzymes
Highly cytotoxic to cancer stem cells in a broad range of malignant diseases
Phase 2 clinical study in metastatic pancreatic cancer in progress
Phase 1/2 studies in recurrent/refractory multiple myeloma and in recurrent pediatric sarcoma expected to begin in the second half of 2020.
Cantex owns issued and pending intellectual property for Dicopp®